by Suzanne George, MD; Richard F. Riedel, MD; and Jonathan C. Trent, MD, PhD
In the current paradigm, non–wild-type metastatic gastrointestinal stromal tumors (GIST) are generally treated in a sequential fashion with imatini......READ MORE
by Suzanne George, MD; Richard F. Riedel, MD; and Jonathan C. Trent, MD, PhD
The management of side effects from tyrosine kinase inhibitor (TKI) therapy often requires a multidisciplinary approach, with aggressive supportive......READ MORE
by Michael C. Heinrich, MD; Arun Singh, MD; and Jonathan C. Trent, MD, PhD
For patients with gastrointestinal stromal tumors (GIST) who are receiving targeted therapy, proactive side effect mitigation strategies can greatl......READ MORE
by Michael C. Heinrich, MD; Arun Singh, MD; and Jonathan C. Trent, MD, PhD
Novel therapies are being developed and clinically tested to overcome the mechanisms of resistance after treatment with the US Food and Drug Admini......READ MORE
by Michael C. Heinrich, MD; Arun Singh, MD; and Jonathan C. Trent, MD, PhD
Patients with gastrointestinal stromal tumors (GIST) now have several options for targeted therapy, and novel therapies are being developed to over......READ MORE
